Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Smith

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2019
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution ExperienceJason P Cooper, Sirin Khajaviyan, Stephen D Smith, et al.
British Journal of Haematology|June 26, 2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myelomaPaul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, et al.
Haematologica|July 20, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factorsSteven Le Gouill, Monika Długosz-Danecka, Simon Rule, et al.
JCO Oncology Practice|May 6, 2020
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle StrategyMary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, et al.
Hematological Oncology|September 20, 2014
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative statusMaika Onishi, Solomon A Graf, Leona Holmberg, et al.
Blood Advances|November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysisAriela Noy, Sven de Vos, Morton Coleman, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
British Journal of Haematology|February 12, 2022
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemiaChaitra Ujjani, Mazyar Shadman, Ryan C Lynch, et al.
British Journal of Haematology|May 3, 2019
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United StatesMarcus Geer, Emily Roberts, Maryann Shango, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2019
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution ExperienceJason P Cooper, Sirin Khajaviyan, Stephen D Smith, et al.
British Journal of Haematology|June 26, 2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myelomaPaul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, et al.
Haematologica|July 20, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factorsSteven Le Gouill, Monika Długosz-Danecka, Simon Rule, et al.
JCO Oncology Practice|May 6, 2020
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle StrategyMary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, et al.
Hematological Oncology|September 20, 2014
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative statusMaika Onishi, Solomon A Graf, Leona Holmberg, et al.
Blood Advances|November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysisAriela Noy, Sven de Vos, Morton Coleman, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
British Journal of Haematology|February 12, 2022
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemiaChaitra Ujjani, Mazyar Shadman, Ryan C Lynch, et al.
British Journal of Haematology|May 3, 2019
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United StatesMarcus Geer, Emily Roberts, Maryann Shango, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Pageof 16